Compare AAL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAL | TGTX |
|---|---|---|
| Founded | 1930 | 1993 |
| Country | United States | United States |
| Employees | 133700 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 7.9B |
| IPO Year | 2004 | 2008 |
| Metric | AAL | TGTX |
|---|---|---|
| Price | $13.79 | $50.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | $15.59 | ★ $49.80 |
| AVG Volume (30 Days) | ★ 58.2M | 2.2M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 0.17 |
| Revenue | ★ $54,633,000,000.00 | $2,785,000.00 |
| Revenue This Year | $12.17 | $49.08 |
| Revenue Next Year | $4.62 | $26.69 |
| P/E Ratio | ★ N/A | $297.41 |
| Revenue Growth | ★ 0.78 | N/A |
| 52 Week Low | $10.09 | $26.76 |
| 52 Week High | $18.79 | $59.30 |
| Indicator | AAL | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 55.26 |
| Support Level | $13.22 | $51.22 |
| Resistance Level | $14.17 | $58.08 |
| Average True Range (ATR) | 0.42 | 1.83 |
| MACD | -0.20 | 0.26 |
| Stochastic Oscillator | 8.02 | 93.86 |
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Dallas/Fort Worth, Charlotte, Chicago, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest average fleet of US legacy carriers.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.